05:23 PM EDT, 03/17/2026 (MT Newswires) -- SAB Biotherapeutics ( SABS ) said late Tuesday it launched a public offering of common shares and pre-funded warrants.

The company will grant underwriters a 30-day overallotment option to buy up to an additional 15% of the securities offered, according to a statement.

Net proceeds will be used to fund the development of the company's clinical stage SAB-142 product candidate, and for general corporate purposes, the company said.